1887

Abstract

The interplay of different inflammatory cytokines induced during dengue virus infection plays a role in either protection or increased disease severity. In this sense, vaccine strategies incorporating whole virus are able to elicit both functional and pathological responses. Therefore, an ideal tetravalent vaccine candidate against dengue should be focused on serotype-specific sequences. In the present work, a new formulation of nucleocapsid-like particles (NLPs) obtained from the recombinant dengue-2 capsid protein was evaluated in mice to determine the level of protection against homologous and heterologous viral challenge and to measure the cytotoxicity and cytokine-secretion profiles induced upon heterologous viral stimulation. As a result, a significant protection rate was achieved after challenge with lethal dengue-2 virus, which was dependent on CD4 and CD8 cells. In turn, no protection was observed after heterologous challenge. In accordance, -stimulated spleen cells from mice immunized with NLPs from the four dengue serotypes showed a serotype-specific response of gamma interferon- and tumour necrosis factor alpha-secreting cells. A similar pattern was detected when spleen cells from dengue-immunized animals were stimulated with the capsid protein. Taking these data together, we can assert that NLPs constitute an attractive vaccine candidate against dengue. They induce a functional immune response mediated by CD4 and CD8 cells in mice, which is protective against viral challenge. In turn, they are potentially safe due to two important facts: induction of serotype specific cell-mediated immunity and lack of induction of antiviral antibodies. Further studies in non-human primates or humanized mice should be carried out to elucidate the usefulness of the NLPs as a potential vaccine candidate against dengue disease.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.037721-0
2012-06-01
2020-06-01
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/6/1204.html?itemId=/content/journal/jgv/10.1099/vir.0.037721-0&mimeType=html&fmt=ahah

References

  1. Balsitis S. J., Williams K. L., Lachica R., Flores D., Kyle J. L., Mehlhop E., Johnson S., Diamond M. S., Beatty P. R., Harris E.. 2010; Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog6:e1000790 [CrossRef][PubMed]
    [Google Scholar]
  2. Bashyam H. S., Green S., Rothman A. L.. 2006; Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol176:2817–2824[PubMed][CrossRef]
    [Google Scholar]
  3. Beaumier C. M., Mathew A., Bashyam H. S., Rothman A. L.. 2008; Cross-reactive memory CD8+ T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J Infect Dis197:608–617 [CrossRef][PubMed]
    [Google Scholar]
  4. Clements D. E., Coller B. A., Lieberman M. M., Ogata S., Wang G., Harada K. E., Putnak J. R., Ivy J. M., McDonell M.. other authors 2010; Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine28:2705–2715 [CrossRef][PubMed]
    [Google Scholar]
  5. Dejnirattisai W., Duangchinda T., Lin C. L., Vasanawathana S., Jones M., Jacobs M., Malasit P., Xu X. N., Screaton G., Mongkolsapaya J.. 2008; A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol181:5865–5874[PubMed][CrossRef]
    [Google Scholar]
  6. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., Puttikhunt C., Edwards C., Duangchinda T.. other authors 2010; Cross-reacting antibodies enhance dengue virus infection in humans. Science328:745–748 [CrossRef][PubMed]
    [Google Scholar]
  7. Dong T., Moran E., Vinh Chau N., Simmons C., Luhn K., Peng Y., Wills B., Phuong Dung N., Thi Thu Thao L.. other authors 2007; High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One2:e1192 [CrossRef][PubMed]
    [Google Scholar]
  8. Friberg H., Burns L., Woda M., Kalayanarooj S., Endy T. P., Stephens H. A., Green S., Rothman A. L., Mathew A.. 2011; Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol89:122–129 [CrossRef][PubMed]
    [Google Scholar]
  9. Gagnon S. J., Zeng W., Kurane I., Ennis F. A.. 1996; Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol70:141–147[PubMed]
    [Google Scholar]
  10. Gagnon S. J., Ennis F. A., Rothman A. L.. 1999; Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocyte clones. J Virol73:3623–3629[PubMed]
    [Google Scholar]
  11. Gil L., López C., Lazo L., Valdés I., Marcos E., Alonso R., Gambe A., Martín J., Romero Y.. other authors 2009; Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol21:1175–1183 [CrossRef][PubMed]
    [Google Scholar]
  12. Green S., Kurane I., Edelman R., Tacket C. O., Eckels K. H., Vaughn D. W., Hoke C. H. Jr, Ennis F. A.. 1993; Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. J Virol67:5962–5967[PubMed]
    [Google Scholar]
  13. Gunther V. J., Putnak R., Eckels K. H., Mammen M. P., Scherer J. M., Lyons A., Sztein M. B., Sun W.. 2011; A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine29:3895–3904 [CrossRef][PubMed]
    [Google Scholar]
  14. Guzmán M. G., Alvarez M., Rodríguez R., Rosario D., Vázquez S., Valdés L., Cabrera M. V., Kourí G.. 1999; Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis3:130–135 [CrossRef][PubMed]
    [Google Scholar]
  15. Halstead S. B.. 1988; Pathogenesis of dengue: challenges to molecular biology. Science239:476–481 [CrossRef][PubMed]
    [Google Scholar]
  16. Halstead S. B.. 1989; Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis11:Suppl. 4S830–S839 [CrossRef][PubMed]
    [Google Scholar]
  17. Hatch S., Endy T. P., Thomas S., Mathew A., Potts J., Pazoles P., Libraty D. H., Gibbons R., Rothman A. L.. 2011; Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis203:1282–1291 [CrossRef][PubMed]
    [Google Scholar]
  18. Imrie A., Meeks J., Gurary A., Sukhbataar M., Kitsutani P., Effler P., Zhao Z.. 2007; Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol81:10081–10091 [CrossRef][PubMed]
    [Google Scholar]
  19. Irie K., Mohan P. M., Sasaguri Y., Putnak R., Padmanabhan R.. 1989; Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene75:197–211 [CrossRef][PubMed]
    [Google Scholar]
  20. Kaufman B. M., Summers P. L., Dubois D. R., Eckels K. H.. 1987; Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg36:427–434[PubMed]
    [Google Scholar]
  21. Khan A. M., Heiny A. T., Lee K. X., Srinivasan K. N., Tan T. W., August J. T., Brusic V.. 2006; Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus. BMC Bioinformatics7:Suppl. 5S4 [CrossRef][PubMed]
    [Google Scholar]
  22. Khan A. M., Miotto O., Nascimento E. J., Srinivasan K. N., Heiny A. T., Zhang G. L., Marques E. T., Tan T. W., Brusic V.. other authors 2008; Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis2:e272 [CrossRef][PubMed]
    [Google Scholar]
  23. Khromykh A. A., Westaway E. G.. 1996; RNA binding properties of core protein of the flavivirus Kunjin. Arch Virol141:685–699 [CrossRef][PubMed]
    [Google Scholar]
  24. Kuhn R. J., Zhang W., Rossmann M. G., Pletnev S. V., Corver J., Lenches E., Jones C. T., Mukhopadhyay S., Chipman P. R., Strauss E. G.. 2002; Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell108:717–725 [CrossRef][PubMed]
    [Google Scholar]
  25. Lazo L., Hermida L., Zulueta A., Sánchez J., López C., Silva R., Guillén G., Guzmán M. G.. 2007; A recombinant capsid protein from dengue-2 induces protection in mice against homologous virus. Vaccine25:1064–1070 [CrossRef][PubMed]
    [Google Scholar]
  26. Libraty D. H., Endy T. P., Houng H. S., Green S., Kalayanarooj S., Suntayakorn S., Chansiriwongs W., Vaughn D. W., Nisalak A.. other authors 2002; Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis185:1213–1221 [CrossRef][PubMed]
    [Google Scholar]
  27. Livingston P. G., Kurane I., Dai L. C., Okamoto Y., Lai C. J., Men R., Karaki S., Takiguchi M., Ennis F. A.. 1995; Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol154:1287–1295[PubMed]
    [Google Scholar]
  28. López C., Gil L., Lazo L., Menéndez I., Marcos E., Sánchez J., Valdés I., Falcón V., de la Rosa M. C.. other authors 2009; In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol154:695–698 [CrossRef][PubMed]
    [Google Scholar]
  29. Mangada M. M., Rothman A. L.. 2005; Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol175:2676–2683[PubMed][CrossRef]
    [Google Scholar]
  30. Mathew A., Kurane I., Rothman A. L., Zeng L. L., Brinton M. A., Ennis F. A.. 1996; Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest98:1684–1691 [CrossRef][PubMed]
    [Google Scholar]
  31. Mongkolsapaya J., Dejnirattisai W., Xu X. N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., Sawasdivorn S., Duangchinda T., Dong T.. other authors 2003; Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med9:921–927 [CrossRef][PubMed]
    [Google Scholar]
  32. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., Khemnu N., Tangthawornchaikul N., Chotiyarnwong P.. other authors 2006; T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J Immunol176:3821–3829[PubMed][CrossRef]
    [Google Scholar]
  33. Morens D. M.. 1994; Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis19:500–512 [CrossRef][PubMed]
    [Google Scholar]
  34. Morens D. M., Halstead S. B., Repik P. M., Putvatana R., Raybourne N.. 1985; Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol22:250–254[PubMed]
    [Google Scholar]
  35. Mukhopadhyay S., Kuhn R. J., Rossmann M. G.. 2005; A structural perspective of the flavivirus life cycle. Nat Rev Microbiol3:13–22 [CrossRef][PubMed]
    [Google Scholar]
  36. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R.. 2002; Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol168:4951–4959[PubMed][CrossRef]
    [Google Scholar]
  37. Rothman A. L.. 2003; Immunology and immunopathogenesis of dengue disease. Adv Virus Res60:397–419 [CrossRef][PubMed]
    [Google Scholar]
  38. Rothman A. L.. 2004; Dengue: defining protective versus pathologic immunity. J Clin Invest113:946–951[PubMed][CrossRef]
    [Google Scholar]
  39. Sabin A. B.. 1952; Research on dengue during World War II. Am J Trop Med Hyg1:30–50[PubMed]
    [Google Scholar]
  40. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., Phanthumachinda B., Halstead S. B.. 1984; Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol120:653–669[PubMed]
    [Google Scholar]
  41. Shresta S., Kyle J. L., Snider H. M., Basavapatna M., Beatty P. R., Harris E.. 2004; Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol78:2701–2710 [CrossRef][PubMed]
    [Google Scholar]
  42. Simmons M., Nelson W. M., Wu S. J., Hayes C. G.. 1998; Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg58:655–662[PubMed]
    [Google Scholar]
  43. Takeshita F., Leifer C. A., Gursel I., Ishii K. J., Takeshita S., Gursel M., Klinman D. M.. 2001; Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol167:3555–3558[PubMed][CrossRef]
    [Google Scholar]
  44. van der Most R. G., Murali-Krishna K., Ahmed R., Strauss J. H.. 2000; Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol74:8094–8101 [CrossRef][PubMed]
    [Google Scholar]
  45. van der Most R. G., Murali-Krishna K., Ahmed R.. 2003; Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Int Immunol15:119–125 [CrossRef][PubMed]
    [Google Scholar]
  46. Vollmer J.. 2006; CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol25:125–134 [CrossRef][PubMed]
    [Google Scholar]
  47. Yauch L. E., Shresta S.. 2008; Mouse models of dengue virus infection and disease. Antiviral Res80:87–93 [CrossRef][PubMed]
    [Google Scholar]
  48. Yauch L. E., Zellweger R. M., Kotturi M. F., Qutubuddin A., Sidney J., Peters B., Prestwood T. R., Sette A., Shresta S.. 2009; A protective role for dengue virus-specific CD8+ T cells. J Immunol182:4865–4873 [CrossRef][PubMed]
    [Google Scholar]
  49. Yauch L. E., Prestwood T. R., May M. M., Morar M. M., Zellweger R. M., Peters B., Sette A., Shresta S.. 2010; CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol185:5405–5416 [CrossRef][PubMed]
    [Google Scholar]
  50. Zellweger R. M., Prestwood T. R., Shresta S.. 2010; Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe7:128–139 [CrossRef][PubMed]
    [Google Scholar]
  51. Zivny J., DeFronzo M., Jarry W., Jameson J., Cruz J., Ennis F. A., Rothman A. L.. 1999; Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J Immunol163:2754–2760
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.037721-0
Loading
/content/journal/jgv/10.1099/vir.0.037721-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error